Merrimack Pharmaceuticals

Health biotech drug development oncology pharma

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA and with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, the Company is building one of the most robust oncology pipelines in the industry.

Market capitalization(2018-06-14)

$120.4 M

Type

Public

Cambridge, US

Founded

2000

Size (employees)

294 (est)

Website

merrimack.com

Merrimack Pharmaceuticals was founded in 2000 and is headquartered in Cambridge, US

Report incorrect company information

Key People/Management at Merrimack Pharmaceuticals

Richard Peters

President and Chief Executive Officer

Report incorrect company information

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has an office in Cambridge

Cambridge, US (HQ)

1 Kendall Square

Show all (1)

Report incorrect company information

Merrimack Pharmaceuticals Financials and Metrics

Merrimack Pharmaceuticals Financials

Merrimack Pharmaceuticals's revenue was reported to be $144.27 m in FY, 2016 which is a 61.6% increase from the previous period.

Summary

USD
Net income (Q1, 2018)	(17.8 m)
Market capitalization (14-Jun-2018)	120.4 m
Closing share price (14-Jun-2018)	9
Cash (31-Mar-2018)	34.3 m

Merrimack Pharmaceuticals's current market capitalization is $120.4 m.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	47.8 m	102.8 m	89.3 m	144.3 m
Revenue growth, %		115%	(13%)	62%
Cost of goods sold				6.9 m
Gross profit				137.4 m

Quarterly

USD	Q1, 2016	Q2, 2016	Q3, 2016
Revenue	21.3 m	33.7 m	28.1 m
Cost of goods sold		1.9 m	1 m
Gross profit		31.8 m	27.1 m
Gross profit Margin, %		94%	96%

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	65.1 m	35.7 m	185.6 m	21.5 m	93.4 m
Accounts Receivable	5.9 m	3.3 m	6.5 m	17.5 m	100 k
Inventories	5.5 m	4.7 m	5.5 m	14.6 m
Current Assets	166.6 m	132.1 m	201.4 m	57.4 m	95 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Cash	105.5 m	66.9 m	77.8 m	100.3 m	28.8 m	33.7 m	56.4 m	48.2 m	21.5 m	36.5 m	17.2 m	135.5 m	34.3 m
Accounts Receivable	8.8 m	12.2 m	6.6 m	2.6 m	4.2 m	1.8 m	2.1 m	15.6 m	19.3 m	22.2 m	43 k	43 k
Inventories								8.1 m	12.3 m	14.8 m
Current Assets	200.3 m	138.9 m	103.8 m	162.1 m	99.3 m	74.9 m	70.9 m	160.7 m	119 m	89.6 m	46.3 m	141.6 m	77.1 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(130.7 m)	(83.6 m)	(147.8 m)	(153.5 m)	470.9 m
Depreciation and Amortization	2.6 m	3.2 m	4.3 m	6.2 m	5.2 m
Inventories	4 m	827 k	(850 k)	(9.7 m)
Accounts Payable

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018
Net Income	(39.8 m)	(27.8 m)	(18.3 m)	(28 m)	(34.4 m)	(22.9 m)	(42.4 m)	(38.7 m)	(51 m)	(30.3 m)	(30.2 m)	(17.8 m)
Depreciation and Amortization												1.2 m
Inventories								8.1 m	12.3 m	14.8 m
Cash From Operating Activities												(17.3 m)